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Abstract Nanoparticles of azithromycin are prepared
using solvent/antisolvent precipitation method. The solu-
bility of drug in water and the oral bioavailability are
increased with decreasing particle size. The effect of type
and concentration of surfactant and feed drug concentration
are evaluated on the precipitated particle size. The nano-
azithromycin in range 200–400 nm is obtained by the
addition of absolute ethanol as solvent, water as antisolvent
in presence of Tween 80 as surfactant. The prepared
nanoparticles are characterized by infra-red spectra, parti-
cle size distribution, scanning electron microscopy, X-ray
diffraction and differential scanning calorimetry. The
chemical structure of nanosized azithromycin does not
show any change but the crystallinity reduces in compari-
son with raw drug. Dissolution of azithromycin nanopar-
ticles in purified water and buffer phosphate (pH of 6.0) is
2.93 and 3.36, respectively, times of raw drug in 30 min.
Keywords Azithromycin  Nanoparticles  Antisolvent 
Bioavailability  Tween 80
Introduction
In the manufacture of pharmaceutical compounds, crys-
tallization is a critical unit operation. So, it is often a key
isolation step or a purification process in the synthesis of an
active pharmaceutical ingredient (API). Crystallization of
an API sometime is critical for product qualities such as
chemical purity and correct polymorphic form, which need
to be strictly controlled to meet set specifications [1].
Optimization of the crystallization process for an API is
important not only for the key product requirements men-
tioned above but also for process efficiency. The API
crystallization process shows a significant effect on
downstream processing. For example, excess fines or wide
particle size distribution may cause slow filtration and
inefficient drying, which may be a major bottleneck of the
entire manufacturing process. It is often necessary to
modify the crystallization process to control particle
properties to facilitate downstream operations [2]. Thus, to
control the particle size and particle size distribution (PSD)
and to improve the stability, it is necessary to increase the
nucleation rate, inhibit the particle growth, and control the
agglomeration of particles by steric or electrostatic stabil-
ization [3–6]. Two main steps in the process of particle
formation are the mixing of the solution and antisolvent
streams to generate supersaturation and the precipitation of
the particles, leading to two main time scales, the mixing
time and the precipitation or induction time [7–9].
If the supersaturation attained is high and is realized
over a very short period of time, then the metastable region
is crossed quickly, the process of nucleation dominates the
crystallization process [10] and a large number of nuclei
are formed, resulting in the precipitation of ultrafine par-
ticles. Physical properties such as particle size, crystal
habit, and surface properties are important aspects of API
product quality and must be considered with great care and
attention during the development of an API crystallization
process [11]. The effort of modifying a crystallization
process to effect changes in the physical properties of
crystals is often called particle engineering [12]. For
insoluble or dissolution-limited drug substances, small
particle size is necessary to maximize surface area to
enhance bioavailability [13]. According to Noyes–Whitney
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equation, the dissolution rate is proportional to the surface
area exposed to the dissolution medium [14]. The crystal-
lization process is a very important stage in production of
active pharmaceutical ingredients. There are many differ-
ent crystallization methods including cooling crystalliza-
tion-based method [15, 16], supercritical fluid-based
methods [17–19], precipitation-based methods [20–22],
and microemulsion techniques [23, 24] and cooling crys-
tallization is a commonly used method that often requires
heating the system to higher temperatures to dissolve all
the crystals. However, as some pharmaceutical compounds
are heat sensitive, elevated temperatures can lead to
decomposition of the compound, resulting in failed bat-
ches. Antisolvent crystallization is usually used for heat-
sensitive compounds and for compounds in which there are
insignificant changes in solubility with temperature [25].
This method requires adding a poor solvent (antisolvent) to
the solution in which the solute is dissolved in, forming a
supersaturated solution that results in the crystallization of
the compound in nanosized form [26, 27]. Many new drugs
are poorly water soluble and their dissolution rates can be
improved by decreasing particle size [28]. Decreasing the
size increases the surface area, which results in an increase
in the rate of dissolution of these drugs in aqueous media
such as body fluids [29]. Azithromycin is absorbed rapidly
after oral administration with a bioavailability of about
36 %. It has a variable effect with food. It is also as a
poorly water-soluble drug. To obtain a good solubility for
azithromycin, we must decrease its particle size.
In recent years, an area that is gaining popularity with
formulation scientists for developing a viable dosage form
for poorly soluble compounds that are moderately potent is
to develop a formulation incorporating drug nanoparticles,
usually\1 lm in diameter. For example, when the particle
size of the drug is reduced from 8 lm to 200 nm there is a
40-fold increase in the surface area to volume ratio [20–24].
Materials and methods
Materials
The used chemicals were with analytical grade and highest
purity. Azithromycin (Fig. 1) dehydrate (SANDOZ Phar-
maceutical Co., PVP K30, Povidone K30, BASF Ger-
many), hydroxypropyl methyl cellulose (ALDRICH
42,321-1, HPMC), polyvinyl acetate (ALDRICH 38,793-2,
PVAc), methyl cellulose (ALDRICH 18,804-2, MC),
hydroxypropyl methyl cellulose phthalate (ALDRICH
43,520-1, HPMC-P), ethanol absolute GR for analysis,
polyvinyl alcohol 72000 for synthesis (PVA), sodium
lauryl sulfate (Ph. Eur., SLS), Tween 80 (Ph. Eur. JP, NF,
polysorbate), triton X-100 GR, polyethylene glycol 400
for synthesis (PEG 400) were used in this work. The
Purified water was used to prepare aqueous solutions and
was obtained by a suitable process. It was prepared from
water complying with the US Environmental Protection
Agency, with conductivity \1.0 ls/cm Pharm. USP.
Preparation of azithromycin nanoparticles
Azithromycin nanoparticles were produced by antisolvent
precipitation method. The ethanol absolute was used as water
miscible solvent. The supersaturation solution (0.556 g/ml)
of azithromycin in ethanol was then filtrated through a
0.4 lm nylon filter membrane to remove solid impurities to
obtain a clear azithromycin solution. The obtained drug
solution was then injected with a rate of 100 ll/s into the
water containing the Tween 80 stabilizer (4.5 mg/ml)
under stirring at 2,500 rpm. Precipitation of solid drug par-
ticles was formed immediately upon mixing at ambient
temperature. The obtained suspension was centrifuged at
15,300 rpm for 30 min and the removed nanoparticles were
washed twice with purified water to remove both the ethanol
and Tween 80. The effect of other stabilizers such as
HPMC, HPMC-P, SLS, PVA, MC, PVAc, Triton X-100,
PVP K30 and PEG 400 on the distribution of nanoparticles
size of azithromycin was also studied.
Water content test
Many pharmaceutical compounds either are hydrates or
contain water in adsorbed form. As a result, determination
of the water content is important in demonstrating com-
pliance with the pharmaceutical standards. A sample
(500 mg) was used as water determent sample. It was
titrated with Karl Fischer pyridine free reagent (according
to USP 34, method I h921i).
Particle size measurement
After the preparation of azithromycin nanoparticles by
antisolvent precipitation method, size of the prepared drug
Fig. 1 Azithromycin structure
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particles was measured immediately after precipitation by
dynamic laser light scattering (Nano-particle size analyzer,
Malvern). Before this measurement, the drug suspension
was diluted by purified water to 0.2 mg/ml.
IR spectra
Shimadzu IR-470 spectrometer was used to record the IR
spectrum of the drugs from 400 to 4,000 cm-1. The sam-
ples were diluted with KBr mixing powder at 1 % (w/w)
and pressed to obtain self-supporting disks.
DSC analysis
Differential scanning calorimetry (DSC) was conducted on
DSC 131 SETARAM. The samples were equilibrated at
20 C for 30 min. Indium standard was used to calibrate
the DSC temperature and enthalpy scale. The samples
(0.1 g) in hermetically sealed aluminum pans were heated
at a temperature range of 20–500 C at 3 C/min. Inert
atmosphere was maintained by purging nitrogen at the flow
rate of 15.8 ml/min, linear velocity 35 cm/s and pressure
24.6 kPa.
Scanning electron microscopy (SEM)
The surface morphologies of the nanosized azithromycin
were observed by scanning electron microscopy (SEM-
AIS-2100) with an accelerating voltage of approximate
1.5–20 kV. Gold coating was performed to prevent charge-
up of sample for 35 s.
Dissolution rate test
Dissolution rate tests were carried out by the USP 34
method, apparatus type I (Basket) (Pharma test, as a dis-
solution tester). The basket speed and bath temperature
were set at 100 rpm and 37.0 ± 0.5 C, respectively. A
250 mg of azithromycin reference standard and nanosized
azithromycin powder were, respectively, added into dif-
ferent vessels containing 900 ml of purified water. This test
was repeated with phosphate buffer (pH = 6.0) and com-
pared obtained results with purified water drug solubility.
In the intervals of 5, 10, 20, 30, 60, 120 min, 2.0 ml aliquot
samples was taken and transferred to a 25-ml volumetric
flask and then diluted with mobile phase to volume and
filtered through 0.45 lm syringe filter. Then, 4.0 ml of this
solution was transferred to a second 25-ml volumetric flask
and diluted with mobile phase to volume. The concentra-
tion of the samples was assayed by a HPLC system
(Waters-Alliance 2690, USA) at 210 nm (USP 34).
Nano-azithromycin purity test (assay)
The solution A was a mixture 60:40 of acetoni-
trile:dipotassium hydrogen phosphate (6.7 g/l and pH
8.0). To prepare test solution, 53.0 mg of the substance
was dissolved in 2 ml of acetonitrile and diluted to
100.0 ml with solution A. Reference solution was pre-
pared by dissolving 53.0 mg of standard azithromycin
in 2 ml of acetonitrile and diluted to 100.0 ml with
solution A.
The system requirements of test are as follows, flow
rate of 1.0 ml/min, column size 4.6 mm 9 25 cm, 5 lm
octadecylsilyl vinyl polymer, column temperature 40 C,
detection system of spectrophotometer at 210 nm, injec-
tion volume of 10 ll and run time of 1.5 times the
retention time of azithromycin. For analysis of impurity
substances, a mixture solvent of ammonium dihydrogen
phosphate (pH = 10):acetonitrile:methanol with ratio
3.5:3.0:3.5 was prepared. To prepare a test solution,
0.200 g of the nano-azithromycin was dissolved in
25.0 ml of the solvent mixture. The conditions of ana-
lysis are as follows: 4.6 mm 9 25 cm column, tempera-
ture 60 C, mobile phase A; 1.80 g/l solution of buffer
phosphate adjusted to pH 8.9, mobile phase B; metha-
nol:acetonitrile (250:750 V/V), flow rate 1.0 ml/min,
detection spectrophotometer at 210 nm and injection
volume 50 ll. Acceptance criteria’s for this analysis is as
follows: impurity B must be \2.0 %; impurities A, C, E,
F, G, H, I, L, M, N, O, P must be \0.5 %; sum of
impurities D and J must be \0.5 %; any other impurities
for each impurity must be \0.2 % and total impurities
must be \3.0 %. All obtained results are cited in
Table 5.
Stability test
According to ICH and WHO guidelines ‘‘Stability testing
of new drug substances and products’’ [Q1A (R2)] and
‘‘Impurities in new drug substances’’ [Q3A (R2)] and sta-
bility conditions for WHO member states by region, Iran is
in zone III a hot and dry place. For samples stored at room
temperature, we must place nano-azithromycin in a rele-
vant tight container at 30 ± 2 C and RH (Relative
Humidity) of 65 ± 5 % for 12 months [7, 30]. At this
work, we use RU MED-Germany stability chamber. About
100 g of nanosized sample was placed in a relevant tight
container and then monitored at 30 C and 65 % of RH for
long-term analysis (12 month). According to the WHO
guideline, the stability results are failing if the significant
change is a 5 % or more in the assay from its initial content
of API.




Azithromycin nanoparticles were prepared by the solvent–
antisolvent precipitation method. The injection of the drug
solution to the antisolvent of water generates high super-
saturation. At these conditions, the nucleation rate is fast
and produces a large number of nuclei, which reduces the
solute mass for subsequent growth. Nanoparticles are
formed while the growth of nucleating crystals is arrested
by the stabilizer (surfactant or polymer) through steric or
electrostatic mechanism [31]. For many hydrophobic
drugs, water is commonly used as the antisolvent. In terms
of the solvent, it is beneficial if it can solubilize the drug in
large amount and possesses a fast diffusion rate in anti-
solvent of water. While the stabilizer needs to have good
affinity for drug particles and possess a fast diffusion rate
and effective adsorption onto the drug particles surface in
solvent/antisolvent mixture. Therefore, solvent–stabilizer
pair is crucial to obtain nanoparticles. Preparation of drug
nanoparticles usually requires a careful selection of stabi-
lizers. In our experiments, ten stabilizers including HPMC,
HPMC-P, SLS, Tween 80, PVA, MC, PVAc, Triton
X-100, PVP K30 and PEG 400 were evaluated. The effects
of stabilizers at a concentration range of 0.5–5.0 %w/v are
studied on precipitated azithromycin particles size and
particles size distribution. The obtained results are shown
in Fig. 2 and sited in Table 1. As seen, in the presence of
Tween 80 as stabilizer, the distribution of nanoparticles
size is obtained at a range of 200–450 nm (Fig. 3).
Characterization of nano-azithromycin
Raw azithromycin and precipitated nanoparticles with
principal peaks at wavenumbers 1721, 1188 and 1052 cm-1
exhibits same IR spectrum as shown in Fig. 4, which
demonstrates that the chemical structure of the drug does
not change with decreasing of particles size in solvent/
antisolvent method.
Fig. 2 Influence of type and concentration of stabilizer on particle
size distribution
Table 1 Influence of type and




Particle size distribution (PSD) (nm)
HPMC HPMC-
P








0.5 10,162 11,521 8,021 7,758 8,305 6,860 8,752 6,566 9,011 9,500
1.0 8,526 9,105 5,281 5,008 6,045 4,602 7,056 4,060 7,210 7,758
1.5 7,690 7,856 4,240 4,027 5,036 3,250 5,525 2,252 6,088 6,230
2.0 6,895 6,522 3,225 3,030 4,138 1,952 4,410 1,651 5,400 5,621
2.5 6,365 6,220 2,324 2,060 2,769 1,265 3,358 1,058 3,984 4,989
3.0 6,023 5,935 1,955 1,445 2,260 1,005 3,126 856 2,511 4,002
3.5 5,852 5,528 1,590 1,273 1,722 855 3,222 657 2,005 3,012
4.0 5,885 5,621 1,002 1,159 1,550 589 3,410 525 2,115 3,121
4.5 6,231 5,978 1,152 1,265 1,368 586 3,518 504 2,599 3,882
5.0 6,322 6,399 1,263 1,328 1,471 729 3,688 586 3,200 4,550
Fig. 3 Nano-azithromycin particle size distribution in 4.5 mg/ml
tween 80 concentration
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The physical state of raw azithromycin and drug nano-
particles is examined by DSC and their thermograms are
shown in Fig. 5. Raw azithromycin exhibits a melting point
at 114.760 ± 0.095 C, with fusion enthalpy of
68.496 ± 0.088 J/g. The melting point and fusion enthalpy
of prepared nanoparticles were 100.238 ± 0.085 C and
35.126 ± 0.150 J/g, respectively. The decrease in thermal
properties shows the decrease in crystallinity in nanopar-
ticles. The DSC analysis of raw and nanoparticles in 3 days
shows the reproducibility of the results (Table 2).
The stability test shows that the prepared nanosuspen-
sion is stable for at least 6 h. The SEM image and the
particle size distribution of the azithromycin nanoparticles,
were obtained from freshly formed nanosuspension, are
shown in Fig. 6a. The morphology of azithromycin
nanoparticles was compared with raw drug optical micro-
scopic view in 4009 zoom in Fig. 6b. The morphology of
raw drug and nanoparticles is the same. SEM image shows
that the size of the nanoparticles is in the range
200–450 nm (Fig. 6c).
The sample X-ray diffraction pattern in Fig. 7 shows
that the main peak is occurred in 2h about 10 and other
important peaks appear at 2h about 6, 9.5, 12, 15.5, 16.5,
17.5 and 18.8. The obtained XRD pattern is same with
XRD pattern of azithromycin dehydrate in the European
Patent application EPO 984020A2 [32].
The mass spectra of nano-azithromycin are shown in
Fig. 8, which are same with that of raw azithromycin [33].
The mass peaks with M/z of 374.1, 375, 749, 750 and 751
reconfirm the molecular structure of nanosized
azithromycin.
Fig. 4 IR spectra of raw drug and nano-azithromycin
Table 2 DSC results of standard azithromycin and nano-azithromy-














1 114.868 68.554 100.283 35.074
2 114.611 68.413 100.314 35.199
3 114.802 68.522 100.119 35.107
Average 114.760 68.496 100.239 35.127
SD 0.109 0.061 0.086 0.053
RSD
(%)
0.095 0.088 0.085 0.151
Fig. 5 DSC spectrum of a raw
drug and b nano-azithromycin
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Assay
Azithromycin is in three crystallization forms, anhydrous
form with water content \2.0 %, monohydrate with water
content between 2.0 and 4.0 % and dihydrate form with
exact water content 4.0–5.0 %. The prepared nanoparticles
show 4.614 ± 0.025 % of water and thus it is a dihydrate
form of azithromycin.
The purity of precipitated nanoparticles was calculated
from British Pharmacopoeia (BP 2010) sixth edition and
show that the precipitated nanoparticles are of highest
purity. Obtained HPLC spectra for standard azithromycin
and precipitated nano-azithromycin show the retention
time of 6.2 min. Analysis of azithromycin nanoparticles
shows that the individual related substances are \0.1 %
and its total impurities are \0.3 % (BP 2010). Thus, the
obtained purity of precipitated nanoparticles was
99.58 ± 0.73 %. All the results from this calculation are
sited in Table 3.
Azithromycin, as a kind of hydrophobic drug, has a low
bioavailability of about 37 % due to its low dissolution
rate. Dissolution profiles of raw azithromycin and precip-
itated nanoparticles at room temperature are illustrated in
Fig. 9. The dissolution rate of azithromycin nanoparticles
is 3.36 ± 0.01 times that of raw drugs (Table 4). Accord-
ing to Noyes–Whitney equation [34], the solid dissolution
rate is directly proportional to its surface area exposed to
the dissolution medium. The accelerated dissolution for
azithromycin nanoparticles is mainly ascribed to their
greater surface area in comparison with raw drug. The
dissolution results in purified water and in buffer phosphate
of pH 6.0 are 2.93 and 3.36 times, respectively, faster than
raw drug in first 30 min. After that, the dissolution has no
significant difference from raw drug.
The precipitated nanoparticles after its initial tests as
mentioned above are placed in a relevant tight container for
12 months in RU MED chamber at a temperature of 30 C
and RH of 65 %. The powder appearance and physical
attributes, assay, impurities, pH and water content are
checked periodically. This analysis was repeated three
times for each test. The obtained results are sited in
Table 5. The obtained results show that there is no sig-
nificant change on appearance and physical attributes, also
the assay and impurity results show the maximum 3.4 %
decrease in the assay from initial potency. Moreover,
obtained results indicate the impurity B is \1.1 %; impu-
rities A, C, E, F, G, H, I, L, M, N, O, P \0.2 %; sum of
impurities D and J are \0.3 %; any other impurities for
each impurity are\0.2 % and total impurities are\1.8 %.
However, increasing impurities during stability conditions
is due to the increase of pH to 10.7 and water content to
4.8 %. The stability results show that the precipitated nano-
azithromycin powder is a stable active pharmaceutical
ingredient.
Conclusion
The solvent/antisolvent precipitation method can be used to
prepare of azithromycin nanoparticles. The ethanol solvent
used to prepare supersaturation solution of drug and
Tween 80 as a stabilizer used to control of particle size
distribution of nanodrug. Azithromycin nanoparticles show
dissolution rate in water as 3.36 times of raw drug. The
Fig. 6 SEM images of a raw drug and nano-azithromycin with
magnification of b 10,000 and c 30,000
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lack of variation in structure and purity of nanodrug are
confirmed by similarity in IR spectra, XRD pattern,
MS spectra and retention time in HPLC of raw and
Table 3 Assay results obtained
from HPLC analysis according
to USP 34, Standard area is
49,540









Fig. 7 XRD pattern of nano-
azithromycin
Fig. 8 Mass spectra of nano-
azithromycin
Fig. 9 Dissolution profile of raw drug and nano-azithromycin
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nano-azithromycin. The obtained particle size distribution
shows that the precipitated nano-azithromycin has a parti-
cle size of about 200–450 nm.
Acknowledgments I would like to thank the research committee of
Islamic Azad University, Shahreza Branch and M. Sc. M. Mansori for
supporting this work.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Mullin, J.W.: Crystallization, 3rd edn, p. 421. Butterworth-He-
inemann, Boston (1993)
2. Lipinski, C.A.: Poor aqueous solubility, an industry wide problem
in drug discovery. Am Pharm ReV 53, 82–85 (2002)
3. Mersmann, A.: Crystallization and precipitation. Chem. Eng. Sci.
38, 345–353 (1999)
4. Dalvi, S.V., Dave, R.N.: Controlling particle size of a poorly
water-soluble drug using ultrasound and stabilizers in antisolvent
precipitation. Ind. Eng. Chem. Res. 48, 7581–7593 (2009)
5. Mosharrafand, M., Nystrom, C.: The effect of particle size and
shape on the surface specific dissolution rate of microsized
practically insoluble drugs. Int. J. Pharm. 122, 35–47 (1995)
6. Muller, R.H., Jacobs, C., Kayser, O.: Nanosuspensions as par-
ticulate drug formulations in therapy. Rationale for development
and what we can expect for the future. Adv. Drug Delivery Rev.
47, 3–19 (2001)
7. Matteucci, M.E., Hotze, M.A., Johnston, K.P., Williams, R.O.:
Drug nanoparticles by antisolvent precipitation: mixing energy
versus surfactant stabilization. Langmuir 22, 8951–8959
(2006)
8. Gradl, J., Schwarzer, H., Schwertfirm, F., Manhart, M., Peukert,
W.: Precipitation of nanoparticles in a T-mixer: coupling the
particle population with hydrodynamics through direct numerical
simulation. Chem. Eng. Process. 45, 908–916 (2006)
9. Johnson, B.K., Prud’homme, R.K.: Flash nanoprecipitation of
organic actives and block copolymers using a confined impinging
jets mixer. Aust. J. Chem. 56, 1021–1024 (2003)
10. Ventosa, N., Veciana, J., Sala, S., Munto, M., Cano, M., Gimeno,
M.: New technologies for the preparation of micro- and nano-
structured materials with potential applications in drug delivery
and clinical diagnostics. Contrib. Sci. 3, 11–20 (2005)
11. Kim, S., Lotz, B., Lindrud, M., Girard, K., Moore, T., Nagarajan,
K., Alvarez, M., Lee, T.: Control of the particle properties of a
drug substance by crystallization engineering and the effect on
drug product formulation. Org. Proc. Res. Dev. 9, 894–901
(2005)
12. Liversidge, G.G., Cundy, K.C.: Particle size reduction for
improvement of oral bioavailability of hydrophobic drugs:
absolute oral bioavailability of nanocrystalline Danzol in beagle
dogs. Int. J. Pharm. 125, 91–97 (1995)
13. Noyes, A.A., Whitney, W.R.: The rate of solution of solid sub-
stances in their own solutions. J. Am. Chem. Soc. 19, 930–934
(1997)
14. Kesisoglou, F., Panmai, S., Wu, Y.: Nanosizing- oral formulation
development and biopharmaceutical evaluation. Adv. Drug
Deliv. Rev. 59, 631–644 (2007)
15. Mullin, J.W., Nyvlt, J.: Programmed cooling of batch crystal-
lizers. Chem. Eng. Sci. 26, 369–377 (1971)
16. Gabas, N., Lague0rie, C.: Batch crystallization of D-xylose by
programmed cooling or by programmed adding of ethanol. Chem.
Eng. Sci. 47, 3145–3148 (1992)
17. Reverchon, E.: Supercritical antisolvent precipitation of micro-
and nano-particles. J. Supercrit. Fluid 15, 1–21 (1999)
18. Charoenchaitrakool, M., Dehghani, F., Foster, N.R.: Microniza-
tion by rapid expansion of supercritical solutions to enhance the
dissolution rates of poorly water-soluble pharmaceuticals. Ind.
Eng. Chem. Res. 39, 4794–4802 (2000)
19. Turk, M., Hils, P., Helfgen, B., Schaber, K., Martin, H.J., Wahl,
M.A.: Micronization of pharmaceutical substances by the rapid
expansion of supercritical solutions (RESS): a promising method
to improve bioavailability of poorly soluble pharmaceutical
agents. J. Supercrit. Fluid 22, 75–84 (2002)
20. Sarkari, M., Brown, J., Chen, X., Swinnea, S., Williams, R.O.,
Johnston, K.P.: Enhanced drug dissolution using evaporative
precipitation into aqueous solution. Int. J. Pharm. 243, 17–31
(2002)
Table 4 The results of
dissolution test of raw and nano-

























10.0 0.82 15.0 1.12 11.5 0.69 27.8 1.01
12.5 1.02 59.0 0.85 42.9 1.33 72.4 0.55
19.8 0.61 76.6 0.88 70.2 1.02 91.0 0.95
24.9 0.77 82.9 0.14 79.8 0.96 96.9 0.66
29.3 0.23 87.5 0.29 83.3 0.20 99.4 0.04
29.8 0.30 87.2 0.66 83.5 0.91 100.0 0.41
Table 5 Stability test results of nano-azithromycin that are placed in
a relevant tight container for 12 months in RU MED chamber at
30 C and 65 % RH condition




Impurity B 1.1 0.02
Impurities A, C, E, F, G, H, I, L, M,
N, O, P
0.2 0.05
Sum of impurities D and J 0.3 0.10
Any other impurities 0.2 0.02
Total impurities 1.8 0.12
103 Page 8 of 9 Int Nano Lett (2014) 4:103
123
21. Bilati, U., Allemann, E., Doelker, E.: Development of a nano-
precipitation method intended for the entrapment of hydrophilic
drugs into nanoparticles. Eur. J. Pharm. Sci. 24, 67–75 (2005)
22. Hua, J., Johnston, K.P., Williams, R.O.: Spray freezing into liquid
(SFL) particle engineering technology to enhance dissolution of
poorly water-soluble drugs: organic solvent versus organic/
aqueous co-solvent systems. Eur. J. Pharmacol. Sci. 20, 295–303
(2003)
23. Debuigne, F., Cuisenaire, J., Jeunieau, L., Masereel, B., Nagy,
J.B.: Synthesis of nimesulide nanoparticles in the microemulsion
epikuron—isopropyl myristate/water/n-butanol (or Isopropanol).
J. Colloid Interface Sci. 243, 90–101 (2001)
24. Trotta, M., Gallarate, M., Carlotti, M.E., Morel, S.: Preparation of
griseofulvin nanoparticles from water-dilutable microemulsions.
Int. J. Pharm. 254, 235–242 (2003)
25. Howard, K.S., Nagy, Z.K., Saha, B., Robertson, A.L., Steele, G.,
Martin, D.A.: Process analytical technology based investigation
of the polymorphic transformations during the antisolvent crys-
tallization of sodium benzoate from IPA/Water mixture. Cryst.
Growth Des. 9, 3964–3975 (2009)
26. O’Grady, D., Barrett, M., Casey, E., Glennon, B.: The effect of
mixing on the metastable zone width and nucleation kinetics in
the anti-solvent crystallization of benzoic acid. Chem. Eng. Res.
Des. Trans 85, 945–952 (2007)
27. Nagy, Z.K., Fujiwara, M., Braatz, R.D.: Modelling and control of
combined cooling and anti-solvent crystallization processes.
J. Process Control 18, 856–864 (2008)
28. Overhoff1, K.A., Johnston, K.P., Robert, O., Williams, R.O.:
Improvement of dissolution rate of poorly water soluble drugs
using a new particle engineering process: spray freezing into
liquid, In: Polymeric Drug Delivery II, Chapter 20, pp 305–319.
(2006)
29. Jie-Xin, W., Qian-Xia, Z., Yue, Z., Lei, Sh, Jian-Feng, Ch.:
Microfluidic synthesis of amorphous cefuroxime axetil nanopar-
ticles with size-dependent and enhanced dissolution rate. Chem.
Eng. J. 16, 844–851 (2010)
30. USP-32th edition, NF-27nd edition. In: Azithromycin; United
state pharmacopeial convention. 12601, Twinbrook Parkway,
Rockville, MD 20852, Vol. 2, pp. 1613–1615. United book press,
Maryland (2008)
31. Yuancai, D., Wai Kiong, N., Shoucang, S.H., Sanggu, K.: Prep-
aration and characterization of spironolactone nanoparticles by
antisolvent precipitation. Int. J. Pharm. 375, 84–88 (2009)
32. Gandhi, R., Pillai, O., Thilagavathi, R.R., Gopalakrishnan, B.,
Kaul, C.L., Panchagnula, R.: Characterization of azithromycin
hydrates. Eur. J. Pharm. Sci. 16, 175–184 (2002)
33. Choemunng, A., Na-Bangchang, K.: An alternative liquid chro-
matography-mass spectrometric method for the determination of
azithromycin in human plasma and its application to pharmaco-
kinetic study of patients with malaria, Southeast Asian. J. Trop.
Med. Public. Health 41, 1048–1058 (2010)
34. Hattori, Y., Haruna, Y., Otsuka, M.: Dissolution process analysis
using model-free Noyes–Whitney integral equation. Colloids
Surf. B Biointerfaces. 102, 227–231 (2013)
Int Nano Lett (2014) 4:103 Page 9 of 9 103
123
